Cell Source, Inc. (CLCS)
OTCMKTS · Delayed Price · Currency is USD
0.9300
+0.1300 (16.25%)
Apr 16, 2026, 9:50 AM EST
Cell Source Market Cap
Cell Source has a market cap or net worth of $54.36 million as of April 16, 2026. Its market cap has increased by 130.86% in one year.
Market Cap
54.36M
Enterprise Value
64.87M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
$0.93
Market Cap Chart
Since July 1, 2014, Cell Source's market cap has increased from 36.03M to 54.36M, an increase of 50.86%. That is a compound annual growth rate of 3.55%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 14, 2026 | 61.15M | 150.51% |
| Dec 31, 2025 | 24.41M | 59.96% |
| Dec 31, 2024 | 15.26M | -14.98% |
| Dec 27, 2023 | 17.95M | -40.09% |
| Dec 29, 2022 | 29.96M | -30.67% |
| Dec 31, 2021 | 43.22M | -32.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 27, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 20, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 27, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vaxart | 168.57M |
| HST Global | 88.40M |
| BioStem Technologies | 82.00M |
| Nuo Therapeutics | 69.54M |
| Vicapsys Life Sciences | 47.26M |
| Harvard Apparatus Regenerative Technology | 27.64M |
| Arch Biopartners | 24.30M |
| Provectus Biopharmaceuticals | 23.07M |